The Society for Immunotherapy of Cancer (SITC) is pleased to offer a highly anticipated series of eight, online seminars to address key questions in the field of cancer immunotherapy, both in-depth and in an easily accessible format.The second seminar in the series, The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets, was held June 29, 2021 from 2-4 PM ET.Moderators:
Presenters:
Program ScheduleTIGIT: the next big thing in checkpoint inhibitors?Ira Mellman, PhD – Genentech, Inc.TIGIT in cancer and autoimmunityDavid A. Hafler, MD – Yale UniversityMechanistic insights on the role of Fc-FcγR co-engagement for anti-TIGIT antibodiesDhan Chand, PhD – AgenusThe TIGIT pathway: PVRIG, a novel pathway memberEran Ophir, PhD – Compugen Ltd.
The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets: Moderators: Jane Grogan, PhD – Graphite Bio, Alan J. Korman, PhD – Vir Biotechnology; Presenters: Dhan Chand, PhD – Agenus, David A. Hafler, MD – Yale University, Ira Mellman, PhD – Genentech, Inc.,Eran Ophir, PhD – Compugen Ltd.; Date June 29, 202102:00:23